X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) surged 40% on Monday after the company reported positive topline data from its Phase 3 X-TOLE2 trial evaluating azetukalner for focal onset seizures.

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain builds its layers and leading to FCD, a primary cause of drug-resistant epilepsy ...